Search

Your search keyword '"Nista, E. C."' showing total 143 results
Start Over Author "Nista, E. C."
143 results on '"Nista, E. C."'

1. Drug-Induced Acute Pancreatitis in Adults: Focus on Antimicrobial and Antiviral Drugs, a Narrative Review

Author

Del Gaudio, Angelo, Covello, Carlo, Di Vincenzo, Federica, De Lucia, Sara Sofia, Mezza, Teresa, Nicoletti, Alberto, Siciliano, V., Candelli, Marcello, Gasbarrini, Antonio, Nista, Enrico Celestino, Del Gaudio A., Covello C., Di Vincenzo F., De Lucia S. S., Mezza T. (ORCID:0000-0001-5407-9576), Nicoletti A., Candelli M. (ORCID:0000-0001-8443-7880), Gasbarrini A. (ORCID:0000-0002-7278-4823), Nista E. C., Del Gaudio, Angelo, Covello, Carlo, Di Vincenzo, Federica, De Lucia, Sara Sofia, Mezza, Teresa, Nicoletti, Alberto, Siciliano, V., Candelli, Marcello, Gasbarrini, Antonio, Nista, Enrico Celestino, Del Gaudio A., Covello C., Di Vincenzo F., De Lucia S. S., Mezza T. (ORCID:0000-0001-5407-9576), Nicoletti A., Candelli M. (ORCID:0000-0001-8443-7880), Gasbarrini A. (ORCID:0000-0002-7278-4823), and Nista E. C.

Abstract

Acute pancreatitis (AP) is an acute inflammation of the pancreas caused by the activation of digestive enzymes in the pancreatic tissue. The main causes of AP are cholelithiasis and alcohol abuse; less commonly, it can be caused by drugs, with a prevalence of up to 5%. Causal associations between drugs and pancreatitis are largely based on case reports or case series with limited evidence. We reviewed the available data on drug-induced AP, focusing on antimicrobial drugs and antivirals, and discussed the current evidence in relation to the classification systems available in the literature. We found 51 suspected associations between antimicrobial and antiviral drugs and AP. The drugs with the most evidence of correlation are didanosine, protease inhibitors, and metronidazole. In addition, other drugs have been described in case reports demonstrating positive rechallenge. However, there are major differences between the various classifications available, where the same drug being assigned to different probability classes. It is likely that the presence in multiple case reports of an association between acute pancreatitis and a drug should serve as a basis for conducting prospective randomized controlled trials to improve the quality of the evidence.

Published
2023

2. Antibiotic Utilization in Acute Pancreatitis: A Narrative Review

Author

Severino, Andrea, Varca, Simone, Airola, Carlo, Mezza, Teresa, Gasbarrini, Antonio, Franceschi, Francesco, Candelli, Marcello, Nista, Enrico Celestino, Severino A., Varca S., Airola C., Mezza T. (ORCID:0000-0001-5407-9576), Gasbarrini A. (ORCID:0000-0002-7278-4823), Franceschi F. (ORCID:0000-0001-6266-445X), Candelli M. (ORCID:0000-0001-8443-7880), Nista E. C., Severino, Andrea, Varca, Simone, Airola, Carlo, Mezza, Teresa, Gasbarrini, Antonio, Franceschi, Francesco, Candelli, Marcello, Nista, Enrico Celestino, Severino A., Varca S., Airola C., Mezza T. (ORCID:0000-0001-5407-9576), Gasbarrini A. (ORCID:0000-0002-7278-4823), Franceschi F. (ORCID:0000-0001-6266-445X), Candelli M. (ORCID:0000-0001-8443-7880), and Nista E. C.

Abstract

Acute pancreatitis is a complex inflammatory disease with significant morbidity and mortality. Despite advances in its management, the role of antibiotics in the prophylaxis and treatment of acute pancreatitis remains controversial. The aim of this comprehensive review is to analyze current evidence on the use of antibiotics in acute pancreatitis, focusing on prophylactic and therapeutic strategies. Prophylactic use aims to prevent local and systemic infections. However, recent studies have questioned the routine use of antibiotics for prophylaxis and highlighted the potential risks of antibiotic resistance and adverse effects. In selected high-risk cases, such as infected necrotizing pancreatitis, prophylactic antibiotic therapy may still be beneficial. As for therapeutic use, antibiotics are usually used to treat infected pancreatic necrosis and extrapancreatic infections. When selecting an antibiotic, the microbiologic profile and local resistance patterns should be considered. Combination therapy with broad-spectrum antibiotics is often recommended to cover both Gram-positive and Gram-negative pathogens. Recent research has highlighted the importance of individualized approaches to antibiotic use in acute pancreatitis and underscored the need for a tailored approach based on patient-specific factors. This review also highlights the potential role of new antimicrobial agents and alternative strategies, such as probiotics, in the management of acute pancreatitis.

Published
2023

3. Effects of functional foods, nutraceuticals, and herbal products on pancreas

Author

Saviano, Angela, Zanza, C., Longhitano, Y., Nista, Enrico Celestino, Franceschi, Francesco, Ojetti, Veronica, Saviano A. (ORCID:0000-0002-2820-7180), Nista E. C., Franceschi F. (ORCID:0000-0001-6266-445X), Ojetti V. (ORCID:0000-0002-8953-0707), Saviano, Angela, Zanza, C., Longhitano, Y., Nista, Enrico Celestino, Franceschi, Francesco, Ojetti, Veronica, Saviano A. (ORCID:0000-0002-2820-7180), Nista E. C., Franceschi F. (ORCID:0000-0001-6266-445X), and Ojetti V. (ORCID:0000-0002-8953-0707)

Abstract

N/A

Published
2023

4. Alpha-Lipoic Acid and Glucose Metabolism: A Comprehensive Update on Biochemical and Therapeutic Features

Author

Capece, Umberto, Moffa, Simona, Improta, I., Di Giuseppe, Gianfranco, Nista, Enrico Celestino, Cefalo, Chiara Maria Assunta, Cinti, Francesca, Pontecorvi, Alfredo, Gasbarrini, Antonio, Giaccari, Andrea, Mezza, Teresa, Capece U., Moffa S., Di Giuseppe G., Nista E. C., Cefalo C. M. A., Cinti F. (ORCID:0000-0001-5170-7055), Pontecorvi A. (ORCID:0000-0003-0570-6865), Gasbarrini A. (ORCID:0000-0002-7278-4823), Giaccari A. (ORCID:0000-0002-7462-7792), Mezza T. (ORCID:0000-0001-5407-9576), Capece, Umberto, Moffa, Simona, Improta, I., Di Giuseppe, Gianfranco, Nista, Enrico Celestino, Cefalo, Chiara Maria Assunta, Cinti, Francesca, Pontecorvi, Alfredo, Gasbarrini, Antonio, Giaccari, Andrea, Mezza, Teresa, Capece U., Moffa S., Di Giuseppe G., Nista E. C., Cefalo C. M. A., Cinti F. (ORCID:0000-0001-5170-7055), Pontecorvi A. (ORCID:0000-0003-0570-6865), Gasbarrini A. (ORCID:0000-0002-7278-4823), Giaccari A. (ORCID:0000-0002-7462-7792), and Mezza T. (ORCID:0000-0001-5407-9576)

Abstract

Alpha-lipoic acid (ALA) is a natural compound with antioxidant and pro-oxidant properties which has effects on the regulation of insulin sensitivity and insulin secretion. ALA is widely prescribed in patients with diabetic polyneuropathy due to its positive effects on nerve conduction and alleviation of symptoms. It is, moreover, also prescribed in other insulin resistance conditions such as metabolic syndrome (SM), polycystic ovary syndrome (PCOS) and obesity. However, several cases of Insulin Autoimmune Syndrome (IAS) have been reported in subjects taking ALA. The aim of the present review is to describe the main chemical and biological functions of ALA in glucose metabolism, focusing on its antioxidant activity, its role in modulating insulin sensitivity and secretion and in symptomatic peripheral diabetic polyneuropathy. We also provide a potential explanation for increased risk for the development of IAS.

Published
2022

5. Endoscopic pancreatic sphincterotomy in patients with IPMN-related recurrent pancreatitis: A single center experience

Author

Schepis, Tommaso, Tringali, Andrea, D'Aversa, F, Perri, Vincenzo, Familiari, Pietro, Boskoski, Ivo, Nista, Enrico Celestino, Costamagna, Guido, Schepis, T, Tringali, A (ORCID:0000-0002-9614-3449), Perri, V (ORCID:0000-0002-0551-0873), Familiari, P (ORCID:0000-0002-5181-2928), Boškoski, I (ORCID:0000-0001-8194-2670), Nista, E C, Costamagna, G (ORCID:0000-0002-8100-2731), Schepis, Tommaso, Tringali, Andrea, D'Aversa, F, Perri, Vincenzo, Familiari, Pietro, Boskoski, Ivo, Nista, Enrico Celestino, Costamagna, Guido, Schepis, T, Tringali, A (ORCID:0000-0002-9614-3449), Perri, V (ORCID:0000-0002-0551-0873), Familiari, P (ORCID:0000-0002-5181-2928), Boškoski, I (ORCID:0000-0001-8194-2670), Nista, E C, and Costamagna, G (ORCID:0000-0002-8100-2731)

Abstract

Acute recurrent pancreatitis (ARP) is a rare manifestation of Intraductal Papillary Mucinous Neoplasms (IPMN) of the pancreas; ARP is a relative indication for pancreatic surgery in the setting of IPMN. Endoscopic pancreatic sphincterotomy (EPS) has been described as a minimal invasive treatment to reduce the episodes of ARP secondary to mucus migration in IPMN.

Published
2022

7. Humoral predictors of malignancy in IPMN: A review of the literature

Author

Nista, Enrico Celestino, Schepis, Tommaso, Candelli, Marcello, Giuli, Lucia, Pignataro, Giulia, Franceschi, Francesco, Gasbarrini, Antonio, Ojetti, Veronica, Nista E. C., Schepis T., Candelli M. (ORCID:0000-0001-8443-7880), Giuli L., Pignataro G., Franceschi F. (ORCID:0000-0001-6266-445X), Gasbarrini A. (ORCID:0000-0002-7278-4823), Ojetti V. (ORCID:0000-0002-8953-0707), Nista, Enrico Celestino, Schepis, Tommaso, Candelli, Marcello, Giuli, Lucia, Pignataro, Giulia, Franceschi, Francesco, Gasbarrini, Antonio, Ojetti, Veronica, Nista E. C., Schepis T., Candelli M. (ORCID:0000-0001-8443-7880), Giuli L., Pignataro G., Franceschi F. (ORCID:0000-0001-6266-445X), Gasbarrini A. (ORCID:0000-0002-7278-4823), and Ojetti V. (ORCID:0000-0002-8953-0707)

Abstract

Pancreatic cystic lesions are increasingly detected in cross-sectional imaging. Intraductal papillary mucinous neoplasm (IPMN) is a mucin-producing subtype of the pancreatic cyst lesions arising from the pancreatic duct system. IPMN is a potential precursor of pancreatic cancer. The transformation of IPMN in pancreatic cancer is progressive and requires the occurrence of low-grade dysplasia, high-grade dysplasia, and ultimately invasive cancer. Jaundice, enhancing mural nodule >5 mm, main pancreatic duct diameter >10 mm, and positive cytology for high-grade dysplasia are considered high-risk stigmata of malignancy. While increased levels of carbohydrate antigen 19-9 (CA 19-9) (>37 U/mL), main pancreatic duct diameter 5–9.9 mm, cyst diameter >40 mm, enhancing mural nodules <5 mm, IPMN-induced acute pancreatitis, new onset of diabetes, cyst grow-rate >5 mm/year are considered worrisome features of malignancy. However, cross-sectional imaging is often inadequate in the prediction of high-grade dysplasia and invasive cancer. Several studies evaluated the role of humoral and intra-cystic biomarkers in the prediction of malignancy in IPMN. Carcinoembryonic antigen (CEA), CA 19-9, intra-cystic CEA, intra-cystic glucose, and cystic fluid cytology are widely used in clinical practice to distinguish between mucinous and non-mucinous cysts and to predict the presence of invasive cancer. Other biomarkers such as cystic fluid DNA sequencing, microRNA (mi-RNA), circulating microvesicles, and liquid biopsy are the new options for the mini-invasive diagnosis of degenerated IPMN. The aim of this study is to review the literature to assess the role of humoral and intracystic biomarkers in the prediction of advanced IPMN with high-grade dysplasia or invasive carcinoma.

Published
2021

9. Assessment of neurological manifestations in hospitalized patients with COVID-19

Author

Luigetti, Marco, Iorio, Raffaele, Bentivoglio, Anna Rita, Tricoli, Luca, Riso, Vittorio, Marotta, Jessica, Piano, Carla, Primiano, Guido Alessandro, Zileri Del Verme, L., Lo Monaco, Maria Rita, Calabresi, Paolo, Abbate, V., Acampora, N., Addolorato, G., Agostini, F., Ainora, M. E., Akacha, K., Amato, E., Andreani, F., Andriollo, G., Annetta, Maria Giuseppina, Annicchiarico, B. E., Antonelli, Massimo, Antonucci, G., Anzellotti, G. M., Armuzzi, A., Baldi, F., Barattucci, I., Barillaro, C., Barone, F., Bellantone, R. D. A., Bellieni, A., Bello, G., Benicchi, A., Benvenuto, F., Berardini, L., Berloco, F., Bernabei, R., Bianchi, A., Biasucci, D. G., Biasucci, L. M., Bibbo, S., Bini, A., Bisanti, A., Biscetti, F., Bocci, M. G., Bonadia, N., Bongiovanni, F., Borghetti, A., Bosco, G., Bosello, Silvia Laura, Bove, V., Bramato, G., Brandi, V., Bruni, T., Bruno, C., Bruno, D., Bungaro, M. C., Buonomo, A., Burzo, L., Calabrese, A., Calvello, M. R., Cambieri, A., Cambise, C., Camma, G., Candelli, M., Canistro, G., Cantanale, A., Capalbo, G., Capaldi, L., Capone, E., Capristo, E., Carbone, L., Cardone, S., Carelli, S., Carfi, A., Carnicelli, A., Caruso, C., Casciaro, F. A., Catalano, L., Cauda, R., Cecchini, A. L., Cerrito, L., Cesarano, M., Chiarito, A., Cianci, Rossella, Cicchinelli, S., Ciccullo, A., Cicetti, M., Ciciarello, F., Cingolani, A., Cipriani, M. C., Consalvo, M. L., Coppola, G., Corbo, G. M., Corsello, A., Costante, F., Costanzi, M., Covino, M., Crupi, D., Cutuli, S. L., D'Addio, S., D'Alessandro, A., D'Alfonso, M. E., D'Angelo, E., D'Aversa, F., Damiano, F., De Berardinis, G. M., De Cunzo, T., De Gaetano, D. K., De Luca, G., De Matteis, G., De Pascale, G., De Santis, P., De Siena, M., De Vito, F., Del Gatto, V., Del Giacomo, P., Del Zompo, F., Dell'Anna, A. M., Della, P. D., Di Gialleonardo, L., Di Giambenedetto, S., Di Luca, R., Di Maurizio, L., Di Muro, M., Dusina, A., Eleuteri, D., Esperide, A., Fachechi, D., Faliero, D., Falsiroli, C., Fantoni, M., Fedele, A., Feliciani, D., Ferrante, C., Ferrone, G., Festa, R., Fiore, M. C., Flex, A., Forte, E., Franceschi, Francesco, Francesconi, A., Franza, L., Funaro, B., Fuorlo, M., Fusco, D., Gabrielli, M., Gaetani, E., Galletta, C., Gallo, A., Gambassi, G., Garcovich, M., Gasbarrini, A., Gasparrini, I., Gelli, S., Giampietro, A., Gigante, L., Giuliano, G., Giupponi, B., Gremese, E., Grieco, Domenico Luca, Guerrera, M., Guglielmi, V., Guidone, C., Gulli, A., Iaconelli, A., Iafrati, A., Ianiro, Gianluca, Iaquinta, A., Impagnatiello, M., Inchingolo, R., Intini, E., Iorio, R., Izzi, I. M., Jovanovic, T., Kadhim, C., La Macchia, R., La Milia, D. I., Landi, F., Landi, G., Landi, R., Landolfi, R., Leo, M., Leone, P. M., Levantesi, L., Liguori, A., Liperoti, R., Lizzio, M. M., Lo Monaco Maria, R., Locantore, P., Lombardi, F., Lombardi, G., Lopetuso, L., Loria, V., Losito, A. R., Lucia, M. B. P., Macagno, F., Macerola, N., Maggi, G., Maiuro, G., Mancarella, F., Mangiola, F., Manno, A., Marchesini, D., Maresca, G. M., Marrone, G., Martis, I., Martone, A. M., Marzetti, Emanuele, Mattana, C., Matteo, M. V., Maviglia, R., Mazzarella, A., Memoli, C., Miele, Luca, Migneco, A., Mignini, I., Milani, A., Milardi, D., Montalto, M., Montemurro, G., Monti, F., Montini, Luca, Morena, T. C., Morra, V., Morretta, C., Moschese, D., Murace, C. A., Murdolo, M., Murri, Rita, Napoli, M., Nardella, E., Natalello, G., Natalini, D., Navarra, S. M., Nesci, A., Nicoletti, A., Nicoletti, R., Nicoletti, T. F., Nicolo, R., Nicolotti, N., Nista, E. C., Nuzzo, E., Oggiano, M., Ojetti, V., Pagano, F. C., Paiano, G., Pais, C., Pallavicini, F., Palombo, A., Paolillo, F., Papa, Alfredo, Papanice, D., Papparella, L. G., Paratore, M., Parrinello, G., Pasciuto, G., Pasculli, P., Pecorini, G., Perniola, S., Pero, E., Petricca, L., Petrucci, M., Picarelli, C., Piccioni, A., Piccolo, A., Piervincenzi, E., Pignataro, G., Pignataro, R., Pintaudi, G., Pisapia, L., Pizzoferrato, M., Pizzolante, F., Pola, R., Policola, C., Pompili, M., Pontecorvi, F., Pontecorvi, V., Ponziani, F., Popolla, V., Porceddu, E., Porfidia, A., Porro, L. M., Potenza, A., Pozzana, F., Privitera, G., Pugliese, D., Pulcini, G., Racco, S., Raffaelli, F., Ramunno, V., Rapaccini, G. L., Richeldi, Luca, Rinninella, Emanuele, Rocchi, S., Romano, B., Romano, S., Rosa, F., Rossi, L., Rossi, R., Rossini, E., Rota, E., Rovedi, F., Rubino, C., Rumi, G., Russo, A., Sabia, L., Salerno, A., Salini, S., Salvatore, L., Samori, D., Sandroni, Claudio, Sanguinetti, M., Santarelli, L., Santini, P., Santolamazza, D., Santoliquido, A., Santopaolo, F., Santoro, M. C., Sardeo, F., Sarnari, C., Saviano, A., Saviano, L., Scaldaferri, Franco, Scarascia, R., Schepis, T., Schiavello, F., Scoppettuolo, G., Sedda, D., Sessa, F., Sestito, L., Settanni, C., Siciliano, M., Siciliano, V., Sicuranza, R., Simeoni, B., Simonetti, J., Smargiassi, A., Soave, P. M., Sonnino, C., Staiti, D., Stella, C., Stella, L., Stival, E., Taddei, E., Talerico, R., Tamburello, E., Tamburrini, E., Tanzarella, E. S., Tarascio, E., Tarli, C., Tersali, A., Tilli, P., Timpano, J., Torelli, E., Torrini, F., Tosato, M., Tosoni, A., Tricoli, L., Tritto, M., Tumbarello, M., Tummolo, A. M., Vallecoccia, M. S., Valletta, F., Varone, F., Vassalli, F., Ventura, G., Verardi, L., Vetrone, L., Vetrugno, G., Visconti, E., Visconti, F., Viviani, A., Zaccaria, R., Zaccone, C., Zelano, L., Zileri Dal Verme, L., Zuccala, G., Luigetti M. (ORCID:0000-0001-7539-505X), Iorio R. (ORCID:0000-0002-6270-0956), Bentivoglio A. R. (ORCID:0000-0002-9663-095X), Tricoli L., Riso V., Marotta J., Piano C., Primiano G., Lo Monaco M. R. (ORCID:0000-0002-1457-7981), Calabresi P. (ORCID:0000-0003-0326-5509), Annetta M. G. (ORCID:0000-0001-7574-1311), Antonelli M. (ORCID:0000-0003-3007-1670), Bosello S. (ORCID:0000-0002-4837-447X), Cianci R. (ORCID:0000-0001-5378-8442), Franceschi F. (ORCID:0000-0001-6266-445X), Grieco D. L. (ORCID:0000-0002-4557-6308), Ianiro G. (ORCID:0000-0002-8318-0515), Marzetti E. (ORCID:0000-0001-9567-6983), Miele L. (ORCID:0000-0003-3464-0068), Montini L. (ORCID:0000-0003-4602-5134), Murri R. (ORCID:0000-0003-4263-7854), Papa A. (ORCID:0000-0002-4186-7298), Richeldi L. (ORCID:0000-0001-8594-1448), Rinninella E. (ORCID:0000-0002-9165-2367), Sandroni C. (ORCID:0000-0002-8878-2611), Scaldaferri F. (ORCID:0000-0001-8334-7541), Luigetti, Marco, Iorio, Raffaele, Bentivoglio, Anna Rita, Tricoli, Luca, Riso, Vittorio, Marotta, Jessica, Piano, Carla, Primiano, Guido Alessandro, Zileri Del Verme, L., Lo Monaco, Maria Rita, Calabresi, Paolo, Abbate, V., Acampora, N., Addolorato, G., Agostini, F., Ainora, M. E., Akacha, K., Amato, E., Andreani, F., Andriollo, G., Annetta, Maria Giuseppina, Annicchiarico, B. E., Antonelli, Massimo, Antonucci, G., Anzellotti, G. M., Armuzzi, A., Baldi, F., Barattucci, I., Barillaro, C., Barone, F., Bellantone, R. D. A., Bellieni, A., Bello, G., Benicchi, A., Benvenuto, F., Berardini, L., Berloco, F., Bernabei, R., Bianchi, A., Biasucci, D. G., Biasucci, L. M., Bibbo, S., Bini, A., Bisanti, A., Biscetti, F., Bocci, M. G., Bonadia, N., Bongiovanni, F., Borghetti, A., Bosco, G., Bosello, Silvia Laura, Bove, V., Bramato, G., Brandi, V., Bruni, T., Bruno, C., Bruno, D., Bungaro, M. C., Buonomo, A., Burzo, L., Calabrese, A., Calvello, M. R., Cambieri, A., Cambise, C., Camma, G., Candelli, M., Canistro, G., Cantanale, A., Capalbo, G., Capaldi, L., Capone, E., Capristo, E., Carbone, L., Cardone, S., Carelli, S., Carfi, A., Carnicelli, A., Caruso, C., Casciaro, F. A., Catalano, L., Cauda, R., Cecchini, A. L., Cerrito, L., Cesarano, M., Chiarito, A., Cianci, Rossella, Cicchinelli, S., Ciccullo, A., Cicetti, M., Ciciarello, F., Cingolani, A., Cipriani, M. C., Consalvo, M. L., Coppola, G., Corbo, G. M., Corsello, A., Costante, F., Costanzi, M., Covino, M., Crupi, D., Cutuli, S. L., D'Addio, S., D'Alessandro, A., D'Alfonso, M. E., D'Angelo, E., D'Aversa, F., Damiano, F., De Berardinis, G. M., De Cunzo, T., De Gaetano, D. K., De Luca, G., De Matteis, G., De Pascale, G., De Santis, P., De Siena, M., De Vito, F., Del Gatto, V., Del Giacomo, P., Del Zompo, F., Dell'Anna, A. M., Della, P. D., Di Gialleonardo, L., Di Giambenedetto, S., Di Luca, R., Di Maurizio, L., Di Muro, M., Dusina, A., Eleuteri, D., Esperide, A., Fachechi, D., Faliero, D., Falsiroli, C., Fantoni, M., Fedele, A., Feliciani, D., Ferrante, C., Ferrone, G., Festa, R., Fiore, M. C., Flex, A., Forte, E., Franceschi, Francesco, Francesconi, A., Franza, L., Funaro, B., Fuorlo, M., Fusco, D., Gabrielli, M., Gaetani, E., Galletta, C., Gallo, A., Gambassi, G., Garcovich, M., Gasbarrini, A., Gasparrini, I., Gelli, S., Giampietro, A., Gigante, L., Giuliano, G., Giupponi, B., Gremese, E., Grieco, Domenico Luca, Guerrera, M., Guglielmi, V., Guidone, C., Gulli, A., Iaconelli, A., Iafrati, A., Ianiro, Gianluca, Iaquinta, A., Impagnatiello, M., Inchingolo, R., Intini, E., Iorio, R., Izzi, I. M., Jovanovic, T., Kadhim, C., La Macchia, R., La Milia, D. I., Landi, F., Landi, G., Landi, R., Landolfi, R., Leo, M., Leone, P. M., Levantesi, L., Liguori, A., Liperoti, R., Lizzio, M. M., Lo Monaco Maria, R., Locantore, P., Lombardi, F., Lombardi, G., Lopetuso, L., Loria, V., Losito, A. R., Lucia, M. B. P., Macagno, F., Macerola, N., Maggi, G., Maiuro, G., Mancarella, F., Mangiola, F., Manno, A., Marchesini, D., Maresca, G. M., Marrone, G., Martis, I., Martone, A. M., Marzetti, Emanuele, Mattana, C., Matteo, M. V., Maviglia, R., Mazzarella, A., Memoli, C., Miele, Luca, Migneco, A., Mignini, I., Milani, A., Milardi, D., Montalto, M., Montemurro, G., Monti, F., Montini, Luca, Morena, T. C., Morra, V., Morretta, C., Moschese, D., Murace, C. A., Murdolo, M., Murri, Rita, Napoli, M., Nardella, E., Natalello, G., Natalini, D., Navarra, S. M., Nesci, A., Nicoletti, A., Nicoletti, R., Nicoletti, T. F., Nicolo, R., Nicolotti, N., Nista, E. C., Nuzzo, E., Oggiano, M., Ojetti, V., Pagano, F. C., Paiano, G., Pais, C., Pallavicini, F., Palombo, A., Paolillo, F., Papa, Alfredo, Papanice, D., Papparella, L. G., Paratore, M., Parrinello, G., Pasciuto, G., Pasculli, P., Pecorini, G., Perniola, S., Pero, E., Petricca, L., Petrucci, M., Picarelli, C., Piccioni, A., Piccolo, A., Piervincenzi, E., Pignataro, G., Pignataro, R., Pintaudi, G., Pisapia, L., Pizzoferrato, M., Pizzolante, F., Pola, R., Policola, C., Pompili, M., Pontecorvi, F., Pontecorvi, V., Ponziani, F., Popolla, V., Porceddu, E., Porfidia, A., Porro, L. M., Potenza, A., Pozzana, F., Privitera, G., Pugliese, D., Pulcini, G., Racco, S., Raffaelli, F., Ramunno, V., Rapaccini, G. L., Richeldi, Luca, Rinninella, Emanuele, Rocchi, S., Romano, B., Romano, S., Rosa, F., Rossi, L., Rossi, R., Rossini, E., Rota, E., Rovedi, F., Rubino, C., Rumi, G., Russo, A., Sabia, L., Salerno, A., Salini, S., Salvatore, L., Samori, D., Sandroni, Claudio, Sanguinetti, M., Santarelli, L., Santini, P., Santolamazza, D., Santoliquido, A., Santopaolo, F., Santoro, M. C., Sardeo, F., Sarnari, C., Saviano, A., Saviano, L., Scaldaferri, Franco, Scarascia, R., Schepis, T., Schiavello, F., Scoppettuolo, G., Sedda, D., Sessa, F., Sestito, L., Settanni, C., Siciliano, M., Siciliano, V., Sicuranza, R., Simeoni, B., Simonetti, J., Smargiassi, A., Soave, P. M., Sonnino, C., Staiti, D., Stella, C., Stella, L., Stival, E., Taddei, E., Talerico, R., Tamburello, E., Tamburrini, E., Tanzarella, E. S., Tarascio, E., Tarli, C., Tersali, A., Tilli, P., Timpano, J., Torelli, E., Torrini, F., Tosato, M., Tosoni, A., Tricoli, L., Tritto, M., Tumbarello, M., Tummolo, A. M., Vallecoccia, M. S., Valletta, F., Varone, F., Vassalli, F., Ventura, G., Verardi, L., Vetrone, L., Vetrugno, G., Visconti, E., Visconti, F., Viviani, A., Zaccaria, R., Zaccone, C., Zelano, L., Zileri Dal Verme, L., Zuccala, G., Luigetti M. (ORCID:0000-0001-7539-505X), Iorio R. (ORCID:0000-0002-6270-0956), Bentivoglio A. R. (ORCID:0000-0002-9663-095X), Tricoli L., Riso V., Marotta J., Piano C., Primiano G., Lo Monaco M. R. (ORCID:0000-0002-1457-7981), Calabresi P. (ORCID:0000-0003-0326-5509), Annetta M. G. (ORCID:0000-0001-7574-1311), Antonelli M. (ORCID:0000-0003-3007-1670), Bosello S. (ORCID:0000-0002-4837-447X), Cianci R. (ORCID:0000-0001-5378-8442), Franceschi F. (ORCID:0000-0001-6266-445X), Grieco D. L. (ORCID:0000-0002-4557-6308), Ianiro G. (ORCID:0000-0002-8318-0515), Marzetti E. (ORCID:0000-0001-9567-6983), Miele L. (ORCID:0000-0003-3464-0068), Montini L. (ORCID:0000-0003-4602-5134), Murri R. (ORCID:0000-0003-4263-7854), Papa A. (ORCID:0000-0002-4186-7298), Richeldi L. (ORCID:0000-0001-8594-1448), Rinninella E. (ORCID:0000-0002-9165-2367), Sandroni C. (ORCID:0000-0002-8878-2611), and Scaldaferri F. (ORCID:0000-0001-8334-7541)

Abstract

Background and purpose: The objective of this study was to assess the neurological manifestations in a series of consecutive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive patients, comparing their frequency with a population hospitalized in the same period for flu/respiratory symptoms, finally not related to SARS-CoV-2. Methods: Patients with flu/respiratory symptoms admitted to Fondazione Policlinico Gemelli hospital from 14 March 2020 to 20 April 2020 were retrospectively enrolled. The frequency of neurological manifestations of patients with SARS-CoV-2 infection was compared with a control group. Results: In all, 213 patients were found to be positive for SARS-CoV-2, after reverse transcriptase polymerase chain reaction on nasal or throat swabs, whilst 218 patients were found to be negative and were used as a control group. Regarding central nervous system manifestations, in SARS-CoV-2-positive patients a higher frequency of headache, hyposmia and encephalopathy always related to systemic conditions (fever or hypoxia) was observed. Furthermore, muscular involvement was more frequent in SARS-CoV-2 infection. Conclusions: Patients with COVID-19 commonly have neurological manifestations but only hyposmia and muscle involvement seem more frequent compared with other flu diseases.

Published
2020

21. Moxifloxacin-Based Anti Helicobacter pylori Therapy

Author

Nista, E. C., Carloni, E., Candelli, M., Cazzato, I. A., Gabrielli, M., Zocco, M. A., Finizio, R., Santarelli, L., Franceschi, F., Di Giorgio, A., Fini, L., Cammarota, G., Gasbarrini, G., and Gasbarrini, A.

Published
2003

35. Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study

Author

Gasbarrini, Antonio, Lauritano, E. C, Nista, E. C, Candelli, M, Gabrielli, Maurizio, Santoro, M, Zocco, M. A, Cazzato, A, Finizio, Rosalba, Ojetti, Veronica, Cammarota, Giovanni, and Gasbarrini, Giovanni Battista

Subjects
Adult, Male, Ofloxacin, Adolescent, Helicobacter pylori, Settore MED/12 - GASTROENTEROLOGIA, Esomeprazole, Pilot Projects, Levofloxacin, Middle Aged, Rifamycins, Rifaximin, Helicobacter Infections, Treatment Outcome, Anti-Infective Agents, Clarithromycin, Humans, Drug Therapy, Combination, Female, Dyspepsia, Enzyme Inhibitors, Aged, Follow-Up Studies
Abstract

Triple therapy is the treatment of choice for Helicobacter pylori-infected patients with an eradication rate ranging from 70 to 85%. Poor compliance and antibiotic resistance are the main causes of treatment failure. The aim of the present study was to assess the efficacy of rifaximin, a poorly absorbed antibiotic, for H. pylori eradication.We enrolled 48 consecutive H. pylori-positive patients affected. They were randomized to receive two 7-day rifaximin-based triple therapies: rifaximin tablets 400 mg t.i.d., esomeprazole 40 mg o.d. and clarithromycin 500 mg b.i.d. (CRE) or levofloxacin 500 mg o.d. (LRE). H. pylori eradication was assessed using a (13)C-urea breath test 4 weeks after the end of therapy. Treatment compliance and the incidence of side effects were also evaluated.No dropouts were observed. The eradication rate both on intention-to-treat and per-protocol analysis did not show significant differences between groups: 58% (14/24 patients) in group 1 and 42% (10/24 patients) in group 2 (p = 0.24, OR 1.96, 95% CI 0.62-6.18). No significant differences in patients' compliance and incidence of side effects were found between groups.Rifaximin-based therapy showed optimal compliance but a limited eradication rate compared to standard first-line treatment. Further investigations are needed to evaluate different dosages and combinations.

Published
2006

36. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.

Author

Zocco, M. A, Dal Verme, L. Z, Cremonini, Filippo, Piscaglia, A. C, Nista, E. C, Candelli, Marcello, Novi, M, Rigante, Donato, Cazzato, I. A, Ojetti, Veronica, Armuzzi, Alessandro, Gasbarrini, Giovanni Battista, Gasbarrini, Antonio, Candelli, Marcello (ORCID:0000-0001-8443-7880), Rigante, Donato (ORCID:0000-0001-7032-7779), Ojetti, Veronica (ORCID:0000-0002-8953-0707), Armuzzi, Alessandro (ORCID:0000-0003-1572-0118), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Zocco, M. A, Dal Verme, L. Z, Cremonini, Filippo, Piscaglia, A. C, Nista, E. C, Candelli, Marcello, Novi, M, Rigante, Donato, Cazzato, I. A, Ojetti, Veronica, Armuzzi, Alessandro, Gasbarrini, Giovanni Battista, Gasbarrini, Antonio, Candelli, Marcello (ORCID:0000-0001-8443-7880), Rigante, Donato (ORCID:0000-0001-7032-7779), Ojetti, Veronica (ORCID:0000-0002-8953-0707), Armuzzi, Alessandro (ORCID:0000-0003-1572-0118), and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

BACKGROUND: Aminosalicylates are the mainstay of therapy to prevent relapse of quiescent ulcerative colitis. The rationale for using probiotics is based on the evidence implicating intestinal bacteria in the pathogenesis of this disorder. AIM: To evaluate the efficacy of Lactobacillus GG alone or in combination with mesalazine vs. mesalazine as maintenance treatment in ulcerative colitis. PATIENTS AND METHODS: 187 ulcerative colitis patients with quiescent disease were randomized to receive Lactobacillus GG 18 x 10(9) viable bacteria/day (65 patients), mesalazine 2400 mg/day (60 patients) or Lactobacillus GG + mesalazine (62 patients). Disease activity index, endoscopic and histological scores were determined at 0, 6 and 12 months and in case of relapse. The primary end point was to evaluate sustained remission. RESULTS: Overall analysis showed no difference in relapse rate at 6 (P = 0.44) and 12 months (P = 0.77) among the three treatment groups. However, the treatment with Lactobacillus GG seems to be more effective than standard treatment with mesalazine in prolonging the relapse-free time (P < 0.05). CONCLUSIONS: Lactobacillus GG seems to be effective and safe for maintaining remission in patients with ulcerative colitis, and it could represent a good therapeutic option for preventing relapse in this group of patients.

Published
2006

37. Characterization of gene expression profile in rat Kupffer cells stimulated with IFN-alpha or IFN-gamma.

Author

Zocco, M. A, Carloni, Emilia, Pesctori, M, Saulnier, Nathalie, Lupascu, Andrea, Nista, E. C, Novi, M, Candelli, M, Cimica, V, Mihm, S, Gasbarrini, Giovanni Battista, Ramadori, G, Gasbarrini, Antonio, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Zocco, M. A, Carloni, Emilia, Pesctori, M, Saulnier, Nathalie, Lupascu, Andrea, Nista, E. C, Novi, M, Candelli, M, Cimica, V, Mihm, S, Gasbarrini, Giovanni Battista, Ramadori, G, Gasbarrini, Antonio, and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

BACKGROUND AND AIM: Kupffer cells are intrasinusoidal space located macrophages with phagocytic capacity. Interferons are cytokines with antiviral, antiproliferative and immunomodulatory activities which may influence the activity of Kupffer cells. Aim of this study was to evaluate Kupffer cell gene expression after interferon-alpha or interferon-gamma stimulation in order to investigate a link between these cytokines and macrophage activation. METHODS: Rat Kupffer cells were cultured for 24 h and divided into three groups: unstimulated; stimulated with interferon-alpha and stimulated with interferon-gamma. After 8 h stimulation total RNA was extracted and processed according to Affymetrix protocols and hybridised on R34A microarray gene set. Data analyses was performed using Microarray Analysis Suite 5.0 software. Genes showing remarkably different expression in microarray analysis were confirmed by real-time PCR. RESULTS: Nearly 4000 out of the 8800 genes represented in the array were expressed by Kupffer cells. Among these, interferon-alpha up-regulates 91 genes by over two-fold (antiviral, antigen processing and presentation, and tumour suppressor/proapoptotic genes) and down-regulates 72 genes by 50% or more. Interferon-gamma up-regulates 70 genes by over two-fold and down-regulates 78 genes by 50% or more. Most of the genes induced by interferon-alpha are also induced by interferon-gamma. Down-regulated genes include growth factors and genes involved in cell cycle/proliferation. Real-time PCR confirms the results of the array. CONCLUSION: Interferons directly target rat Kupffer cells and are involved in the regulation of a wide variety of genes. Their expression profile shed light onto molecular mechanism of Kupffer cells activation in specific pathways such as antiviral and antitumour processes.

Published
2006

38. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis

Author

Zocco, Maria Assunta, Dal Verme, L. Z., Cremonini, Filippo, Piscaglia, Anna Chiara, Nista, Enrico Celestino, Candelli, Marcello, Novi, M., Rigante, Donato, Cazzato, I. A., Ojetti, Veronica, Armuzzi, Alessandro, Gasbarrini, Giovanni Battista, Gasbarrini, Antonio, Zocco M. A. (ORCID:0000-0002-0814-9542), Cremonini F., Piscaglia A. C., Nista E. C., Candelli M. (ORCID:0000-0001-8443-7880), Rigante D. (ORCID:0000-0001-7032-7779), Ojetti V. (ORCID:0000-0002-8953-0707), Armuzzi A. (ORCID:0000-0003-1572-0118), Gasbarrini G., Gasbarrini A. (ORCID:0000-0002-7278-4823), Zocco, Maria Assunta, Dal Verme, L. Z., Cremonini, Filippo, Piscaglia, Anna Chiara, Nista, Enrico Celestino, Candelli, Marcello, Novi, M., Rigante, Donato, Cazzato, I. A., Ojetti, Veronica, Armuzzi, Alessandro, Gasbarrini, Giovanni Battista, Gasbarrini, Antonio, Zocco M. A. (ORCID:0000-0002-0814-9542), Cremonini F., Piscaglia A. C., Nista E. C., Candelli M. (ORCID:0000-0001-8443-7880), Rigante D. (ORCID:0000-0001-7032-7779), Ojetti V. (ORCID:0000-0002-8953-0707), Armuzzi A. (ORCID:0000-0003-1572-0118), Gasbarrini G., and Gasbarrini A. (ORCID:0000-0002-7278-4823)

Abstract

Background Aminosalicylates are the mainstay of therapy to prevent relapse of quiescent ulcerative colitis. The rationale for using probiotics is based on the evidence implicating intestinal bacteria in the pathogenesis of this disorder.Aim To evaluate the efficacy of Lactobacillus GG alone or in combination with mesalazine vs. mesalazine as maintenance treatment in ulcerative colitis.Patients and methods 187 ulcerative colitis patients with quiescent disease were randomized to receive Lactobacillus GG 18 x 10(9) viable bacteria/day (65 patients), mesalazine 2400 mg/day (60 patients) or Lactobacillus GG + mesalazine (62 patients). Disease activity index, endoscopic and histological scores were determined at 0, 6 and 12 months and in case of relapse. The primary end point was to evaluate sustained remission.Results Overall analysis showed no difference in relapse rate at 6 (P = 0.44) and 12 months (P = 0.77) among the three treatment groups. However, the treatment with Lactobacillus GG seems to be more effective than standard treatment with mesalazine in prolonging the relapse-free time (P < 0.05).Conclusions Lactobacillus GG seems to be effective and safe for maintaining remission in patients with ulcerative colitis, and it could represent a good therapeutic option for preventing relapse in this group of patients.

Published
2006

39. Decreased mitochondrial oxidative capacity in hereditary tyrosinemia type 1

Author

Rigante, Donato, Gasbarrini, Antonio, Nista, Enrico Celestino, Candelli, Marcello, Rigante D. (ORCID:0000-0001-7032-7779), Gasbarrini A. (ORCID:0000-0002-7278-4823), Nista E. C., Candelli M. (ORCID:0000-0001-8443-7880), Rigante, Donato, Gasbarrini, Antonio, Nista, Enrico Celestino, Candelli, Marcello, Rigante D. (ORCID:0000-0001-7032-7779), Gasbarrini A. (ORCID:0000-0002-7278-4823), Nista E. C., and Candelli M. (ORCID:0000-0001-8443-7880)

Abstract

A pediatric case of decreased mitochondrial oxidative capacity is herein presented and related to hereditary tyrosinemia type 1

Published
2005

40. Anti-Saccharomyces cerevisiae antibodies and coeliac disease

Author

Candelli, Marcello, Nista, Enrico Celestino, Carloni, E., Pignataro, Giulia, Rigante, Donato, Gasbarrini, Antonio, Candelli M. (ORCID:0000-0001-8443-7880), Nista E. C., Pignataro G., Rigante D. (ORCID:0000-0001-7032-7779), Gasbarrini A. (ORCID:0000-0002-7278-4823), Candelli, Marcello, Nista, Enrico Celestino, Carloni, E., Pignataro, Giulia, Rigante, Donato, Gasbarrini, Antonio, Candelli M. (ORCID:0000-0001-8443-7880), Nista E. C., Pignataro G., Rigante D. (ORCID:0000-0001-7032-7779), and Gasbarrini A. (ORCID:0000-0002-7278-4823)

Abstract

The relationship between anti-Saccharomyces cerevisiae antibodies and coeliac disease is explored and discussed

Published
2003

45. Raynaud's phenomenon and celiac disease

Author

Gabrielli, M., primary, Candelli, M., additional, Santarelli, L., additional, Nista, E. C., additional, Santoliquido, A., additional, Gasbarrini, G., additional, Pola, P., additional, and Gasbarrini, A., additional

Published
2003
Full Text
View/download PDF

46. Levofloxacin-based triple therapy vs. quadruple therapy in second-lineHelicobacter pyloritreatment: a randomized trial

Author

Nista, E. C., primary, Candelli, M., additional, Cremonini, F., additional, Cazzato, I. A., additional, Di Caro, S., additional, Gabrielli, M., additional, Santarelli, L., additional, Zocco, M. A., additional, Ojetti, V., additional, Carloni, E., additional, Cammarota, G., additional, Gasbarrini, G., additional, and Gasbarrini, A., additional

Published
2003
Full Text
View/download PDF

47. Breath testing for human liver function assessment

Author

Armuzzi, A., primary, Candelli, M., additional, Zocco, M. A., additional, Andreoli, A., additional, De Lorenzo, A., additional, Nista, E. C., additional, Miele, L., additional, Cremonini, F., additional, Cazzato, I. A., additional, Grieco, A., additional, Gasbarrini, G., additional, and Gasbarrini, A., additional

Published
2002
Full Text
View/download PDF

48. 13C-methionine breath tests for mitochondrial liver function assessment.

Author

CANDELLI, M., MIELE, L., ARMUZZI, A., NISTA, E. C., PIGNATARO, G., FINI, L., CAZZATO, I. A., ZOCCO, M. A., BARTOLOZZI, F., GASBARRINI, G., GRIECO, A., and GASBARRINI, A.

Abstract

13C-methionine breath test has been proposed as a non-invasive tool for the assessment of human hepatic mithocondrial function. Two methionine breath labeled with 13C in differents point of his molecular structure have been used for breath test analisys. Aim of this study was to compare two differently 13C-labeled methionines in the evaluation of mitochondrial oxidation in basal conditions and after an acute oxidative stress. 15 healthy male subjects (mean age 30.5 ± 3.1) received [methyl-13C]-methionine dissolved in water. Breath samples were taken at baseline and and 10, 20, 30, 45, 60, 75, 90, 105 and 120 minutes after the ingestion of the labeled substrate. Forthy-eight hours later, subjects underwent the same test 30 minutes after ethanol ingestion (0,3 g/kg of body weight). Seven-day later, subjects underwent breath test using (L-methionine-1-13COOH) as substrate, in basal condition and after ethanol ingestion. At basal condition, the cumulative percentage of 13CO2 recovered in breath during the test period (%cum-dose) was higher using L-methionine-1-13COOH than [methyl-13C]-methionine (10.25 ± 1.0 vs 4.07 ± 0.8; p < 0.01). After ethanol ingestion, % cum dose was significantly decreased at 60 and 120 minutes with both methionines (120 min: 10.25 ± 1.0 vs 5.03% ± 1.8; < 0.01 and 4.07 ± 0.8 vs 2.16% ± 0.9; p < 0.01, respectively). However, %cum-dose during L-methionine-1-13C-breath test was significantly lower than that observed during methyl-13C-methionine breath test (120 minutes: 5.03% ± 1.8 vs 2.16% ± 0.9; p < 0.01) In conclusion, breath test based on L-methionine-1-13COOH seems to show a greater reliability when compared to [methyl-13C]-methionine to assess mitochondrial function because a larger amount of labeled carbon that reaches the Krebs' cicle. [ABSTRACT FROM AUTHOR]

Published
2008

49. Gender affects 13C-ketoisocaproic acid breath test.

Author

Candelli, M., Armuzzi, A., Miele, L., Nista, E. C., Pignataro, G., Dal Verme, L. Zileri, Grieco, A., Gasbarrini, G., and Gasbarrini, A.

Abstract

Background and Aims: 13C-Ketoisocaproic Acid Breath Test (13C-Kica-BT) has been proposed to assess mitochondrial function. Aim of this study is to evaluate whether gender affects mithocondrial oxidation by means of 13C-Kica-BT in healthy subjects in basal conditions and after an acute oxidative stress induced by ethanol. Methodology: 50 healthy volunteers were given 1 mg/kg of 13C-Kica together with 20 mg/kg of L-leucine dissolved in 200 ml of orange juice. Breath samples were taken at baseline, every 5 minutes for 45 minutes and then every 15 minutes until 2 hours. Forty-eight hours later the test was repeated 30 min after ethanol ingestion (0.5 g/kg body weight). 13CO2 enrichment in breath was analyzed by isotope ratio/mass spectrometry. Statistical analysis was performed using the student's t test. Results: At baseline conditions, the percentage of Ketoisocaproic acid in 2 hours was significantly higher in females than in males. Ethanol significantly reduces the oxidation of Ketoisocaproic acid. Conversely, no differences were observed between groups after the ethanol oral load. Conclusions: Decarboxylation of 13C-Kica was significantly higher in females than in males. Ethanol decreases Kica decarboxylation in particular in women. Further studies remain needed to establish whether sexual hormones could interfere with the metabolism of Kica. [ABSTRACT FROM AUTHOR]

Published
2007

50. A case-control study comparing methylene blue directed biopsies and random biopsies for detecting pre-cancerous lesions in the follow-up of gastric cancer patients.

Author

Ojetti, V., Persiani, R., Nista, E. C., Rausei, S., Lecca, G., Migneco, A., Cananzi, F. C. M., Cammarota, G., D'ugo, D., Gasbarrini, G., and Gasbarrini, A.

Abstract

Objectives: To compare the accuracy of Methylene Blue (MB) targeted biopsies with random biopsies in detecting intestinal metaplasia and dysplasia in the follow-up of patients after gastrectomy for gastric cancer. Methods: Thirty patients (21 Billroth II, 9 Billroth I) for cancer, referred to the Gastroenterology Unit for an elective esophagogastroduodenoscopy (EGD), were enrolled. All endoscopies were performed with a high-resolution videoendoscope with an adjustable image magnification: EG-485ZH (Fujinon, Omiya, Japan). During EGD three random biopsies were taken in the stomach and, after staining with MB, three targeted biopsies were taken from every stained area. Results: In 28 patients traditional endoscopy showed hyperemia of the anastomosis, in 2 patients a lesion. After MB in 6/30 there were stained area (2 lesions seen with traditional endoscopy and 4 blue areas in other patients). As regards hystology: 24 patients showed inflammation, while 2 patients with alterations in traditional endoscopy and with MB showed metaplasia and high grade dysplasia. In 4/30 (13.3%) patients MB guided biopsies showed significant lesions (3 intestinal metaplasia, 1 low grade dysplasia) while random biopsies showed only inflammation. Conclusions: After partial gastrectomy, the mucosa of the residual stomach usually undergoes severe changes, and these lesions are known to be pre-cancerous. The diagnostic accuracy of the MB technique seems to be superior to random biopsies for identification of intestinal metaplasia, dysplasia, and may be helpful in targeting biopsies and early endoscopic treatment. [ABSTRACT FROM AUTHOR]

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results